Abstract：
Inflammatory bowel disease (IBD) is a chronic relapsing disease of the gastrointestinal (GI) system that includes two groups, Crohn\'s disease (CD) and ulcerative colitis (UC). To cope with these two classes of IBD, the investigation of pathogenic mechanisms and the discovery of new diagnostic and therapeutic approaches are crucial. Long non-coding RNAs (lncRNAs) which are non-coding RNAs with a length of longer than 200 nucleotides have indicated significant association with the pathology of IBD and strong potential to be used as accurate biomarkers in diagnosing and predicting responses to the IBD treatment. In the current review, we aim to investigate the role of lncRNAs in the pathology and development of IBD. We first describe recent advances in research on dysregulated lncRNAs in the pathogenesis of IBD from the perspective of epithelial barrier function, intestinal immunity, mitochondrial function, and intestinal autophagy. Then, we highlight the possible translational role of lncRNAs as therapeutic targets, diagnostic biomarkers, and predictors of therapeutic response in colon tissues and plasma samples. Finally, we discuss the potential of extracellular vesicles and their lncRNA cargo in the pathophysiology, diagnosis, and treatment of IBD.
摘要：
炎症性肠病（IBD）是胃肠道（GI）系统的慢性复发性疾病，包括两组，克罗恩病（CD）和溃疡性结肠炎（UC）。为了应对这两类IBD，致病机制的研究以及新的诊断和治疗方法的发现至关重要。作为长度长于200个核苷酸的非编码RNA的长的非编码RNA(lncRNA)已经表明与IBD的病理学显著关联并且在诊断和预测对IBD治疗的响应中用作准确的生物标志物的强潜力。在当前的审查中，我们的目的是研究lncRNAs在IBD病理和发展中的作用。我们首先从上皮屏障功能的角度描述了在IBD发病机制中失调的lncRNAs的研究进展。肠道免疫,线粒体功能，和肠道自噬。然后，我们强调了lncRNAs作为治疗靶标的可能的翻译作用，诊断生物标志物，以及结肠组织和血浆样品中治疗反应的预测因子。最后,我们讨论了细胞外囊泡及其lncRNA货物在病理生理学中的潜力，诊断,和IBD的治疗。
